70 / 100 SEO Score

chenguang zhang | Endocrine Pharmacology | Best Researcher Award

Dr. chenguang zhang at The Tumor Hospital of Xinjiang Medical University, China.

Dr. Chenguang Zhang 🧑‍⚕️ is a distinguished breast cancer surgeon and researcher, renowned for his expertise in diagnosing and treating both benign and malignant breast tumors. 🩺 He excels in surgeries including mastectomy, breast-conserving techniques, and reconstruction. 🧬 His cutting-edge research focuses on endocrine therapy resistance and molecular mechanisms in breast cancer, leading multiple high-level funded projects. 🔬 He holds a patent for surgical forceps 🛠️ and has authored numerous publications in SCI-indexed journals 📚. As a committed academic and member of several prestigious medical associations 🤝, Dr. Zhang is driving innovation in cancer diagnosis, treatment, and personalized care.

Publication Profile 

Orcid

Education

Dr. Chenguang Zhang 🧑‍⚕️ is highly proficient in the differential diagnosis of benign and malignant breast tumors 🔬. He is skilled in advanced breast cancer surgical techniques, including modified radical mastectomy, breast-conserving surgery, sentinel lymph node biopsy, and both implant-based and autologous tissue breast reconstruction 🏥. His research primarily targets the mechanisms behind endocrine therapy resistance in breast cancer 🎯. A leader in scientific innovation, he has directed multiple high-impact research projects at provincial and ministerial levels 🧪📊. Dr. Zhang’s commitment to precision medicine and surgical excellence is shaping the future of breast oncology care.

Professional Memberships

Dr. Chenguang Zhang 🧑‍⚕️ is an active contributor to the advancement of breast oncology through multiple prestigious professional memberships 🤝. He is a member of the Young Scholars Group of Breast Oncology under the Oncology Branch of the Chinese Medical Association 🧬, and serves on the Professional Committee of Oncoplastic Surgery within the China Anti-Cancer Association 🎗️. He is part of the Youth Expert Group 🌟 and the Young Scholars Group of the Science Popularization Branch of the Chinese Medical Doctor Association 📚. Additionally, he contributes to the Breast Minimally Invasive Plastic Surgery and Reconstruction Group within the Rehabilitation Society of the China Anti-Cancer Association.

Research Focus 

Dr. Chenguang Zhang’s research 🧪 focuses on breast cancer biology 🩺, particularly triple-negative breast cancer (TNBC) and endocrine therapy resistance in ER-positive tumors. His studies explore molecular pathways such as PI3K/AKT/mTOR, Wnt signaling, ferroptosis regulation, and autophagy inhibition 🧬. He investigates prognostic biomarkers, drug resistance mechanisms 💊, and advanced surgical strategies including sentinel lymph node biopsy and reconstructive techniques 🔬. His work contributes significantly to precision oncology, translational medicine, and clinical innovation in breast tumor management 🎗️. With a strong emphasis on molecular diagnostics, therapeutic resistance, and immunological responses, his research advances breast cancer treatment outcomes globally.

Publication Top Notes

  • Typical presentation of neurofibromatosis type I in a patient with giant cutaneous neoplasm and café au lait spots: A case report.
  • FOXO4 suppresses cisplatin resistance of triple-negative breast cancer by inhibiting autophagy.
  • Leveraging senescence-oxidative stress co-relation to predict prognosis and drug sensitivity in breast invasive carcinoma.
  • A degradome-based prognostic signature that correlates with immune infiltration and tumor mutation burden in breast cancer.
  • MET and FASN as Prognostic Biomarkers of Triple Negative Breast Cancer: A Systematic Evidence Landscape of Clinical Study.
  • HOXD Antisense Growth-Associated Long Noncoding RNA Promotes Triple-Negative Breast Cancer Progression by Activating Wnt Signaling Pathway.
  • Clinical study of combined application of indocyanine green and methylene blue for sentinel lymph node biopsy in breast cancer.
  • Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer.
  • Expression analysis of E-cad and vascular endothelial growth factor in triple-negative breast cancer patients of different ethnic groups in western China.
chenguang zhang | Endocrine Pharmacology | Best Researcher Award

You May Also Like